



## **Bachem Enlarges Corporate Executive Committee**

### **Dr. Lester Mills assumes responsibility for global Marketing and Sales**

Bubendorf/Basel, Switzerland, September 17, 2008 - Bachem (SWX: BANB) announced today that Dr. Lester Mills will become the fourth member of the company's Corporate Executive Committee on January 1, 2009. Lester Mills will be responsible for global Marketing and Sales and will strengthen the existing team of Rolf Nyfeler, Chief Executive Officer, Daniel Erne, Chief Technology Officer, and Michael Hüsler, Chief Financial Officer.

Lester Mills, aged 49, who has dual British and Swiss nationality, studied Chemistry at the University of Cambridge, England, and then obtained his Ph.D. at the University of East Anglia, England. In the course of his professional career he added to his specialist qualifications with an MBA from the State University of New York, Albany, NY, USA. Lester Mills has extensive international industrial experience from his previous work in the USA and Switzerland. After starting his career as a research chemist at Lonza, he soon turned his attention to the commercial side of the business and had various management functions in Marketing and Purchasing with Genzyme and then with Roche Vitamins, today DSM Nutritional Products. At present he is Director of Sales at DSM Nutritional Products Europe, Birsfelden, Switzerland.

Rolf Nyfeler, CEO of Bachem, commented: "In Lester Mills we have succeeded in attracting a highly qualified and internationally experienced professional to our company. Thanks to his earlier work with Genzyme, he also has detailed knowledge already of our core business, the peptide market. In face of the increasing globalization and continuous growth of our business, we expect Lester Mills to bring a dynamic impetus to the newly created executive committee function for Marketing and Sales and thereby contribute substantially to the further development of Bachem."

With the creation of the new Corporate Executive Committee function, the Marketing and Sales unit at Bachem will be restructured and further expanded to take account of the sustained global interest in and steadily growing demand for its products and services.

### **About Bachem**

Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.

For further questions, please contact:

Bachem Holding AG  
Michael Hüsler, CFO  
Tel.: +41 61 935 2333  
Fax: +41 61 935 2324

[www.bachem.com](http://www.bachem.com)  
[ir@bachem.com](mailto:ir@bachem.com)